Trastuzumab deruxtecan - CAS 1826843-81-5

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd) . Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Antibody-Drug Conjugates (ADCs), EGFR

Angiogenesis, JAK/STAT signaling, Tyrosine Kinase/Adaptors, Antibody-drug Conjugate/ADC Related

1826757

0.9849

-20°C

Ice Packs

Inhibitory Antibodies